PinnyPeptide

FTPP-Adipotide vs Survodutide

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

FTPP-Adipotide

Weight Management

Vasculature-targeting peptide that selectively destroys adipose blood vessels.

Peptide B

Survodutide

Weight Management

Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials.

Typical vial

5 mg

Typical dose

Per kg dosing (research-only) mcg

Half-life

~hours

FDA status

Not FDA approved.

Typical vial

10 mg

Typical dose

300-6000 mcg

Half-life

~80-90 hours (once-weekly dosing)

FDA status

Not FDA approved. Investigational compound in phase 3 clinic…

FTPP-Adipotide effects

  • Selective destruction of white adipose tissue vasculature
  • Rapid weight and fat loss in primate models
  • Improved insulin sensitivity
  • Brown adipose tissue largely spared
  • Mechanism distinct from lipolytic / appetite-suppressing peptides

Survodutide effects

  • Substantial weight loss (~14-19% at highest doses in phase 2)
  • Suppresses appetite and slows gastric emptying via GLP-1
  • Increases energy expenditure via glucagon receptor activation
  • Reduces liver fat (notable MASH/NASH activity)
  • Improves glycemic control and fasting glucose
  • Lowers LDL cholesterol and triglycerides

FTPP-Adipotide side effects

  • Renal toxicity (prohibitin expressed in kidney vasculature) — significant safety concern
  • Possible damage to other prohibitin-expressing vascular beds
  • Injection-site reactions
  • Limited human safety data
  • Acute inflammatory response from adipose vascular death

Survodutide side effects

  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea or constipation
  • Decreased appetite
  • Transient heart rate increase (5-10 bpm)
  • Injection site reactions
  • Mild fasting glucose elevation at low doses (resolves with titration)
  • Risk of gallbladder issues with rapid weight loss

FTPP-Adipotide dosing ranges

Animal research (rhesus monkey model)

0.43 mg/kg · Daily SubQ × 28 days · Per published protocol

Human self-experimentation

Not recommended · — · —

Survodutide dosing ranges

Obesity (phase 2/3 protocol)

0.3-6.0 mg · Once weekly SubQ (titrated) · Long-term (chronic dosing)

MASH / NASH (phase 2)

1.2-6.0 mg · Once weekly SubQ (titrated) · 48 weeks minimum

Type 2 diabetes (phase 2)

0.3-4.8 mg · Once weekly SubQ · Long-term

FTPP-Adipotide vs Survodutide — common questions

What is the difference between FTPP-Adipotide and Survodutide?

FTPP-Adipotide: Vasculature-targeting peptide that selectively destroys adipose blood vessels. Typical dose Per kg dosing (research-only) mcg. Survodutide: Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials. Typical dose 300-6000 mcg. Both fall under the Weight Management category.

Can you stack FTPP-Adipotide and Survodutide?

Stacking FTPP-Adipotide with Survodutide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, FTPP-Adipotide or Survodutide?

FTPP-Adipotide is typically dosed: Daily SubQ × 28 days for Animal research (rhesus monkey model); — for Human self-experimentation. Survodutide is typically dosed: Once weekly SubQ (titrated) for Obesity (phase 2/3 protocol); Once weekly SubQ (titrated) for MASH / NASH (phase 2); Once weekly SubQ for Type 2 diabetes (phase 2).

Are FTPP-Adipotide and Survodutide FDA approved?

FTPP-Adipotide: Not FDA approved. Survodutide: Not FDA approved. Investigational compound in phase 3 clinical trials for obesity and MASH/NASH.

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free